NINA SHARMA: Open Payments
NPI 1205419777 · SPARKS, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$7,283 in 332 payments from 48 companies in 2025. Trend: 2023 $8,231 · 2024 $5,197 · 2025 $7,283
Food & beverage: $7,183Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $738 |
| Novartis Pharmaceuticals Corporation | 28 | $548 |
| EMD Serono, Inc. | 19 | $542 |
| Biogen, Inc. | 18 | $360 |
| Vanda Pharmaceuticals Inc. | 23 | $333 |
| Axsome Therapeutics, Inc. | 10 | $268 |
| Janssen Biotech, Inc. | 7 | $260 |
| ARGENX US, INC. | 9 | $256 |
| Celgene Corporation | 20 | $230 |
| Lilly USA, LLC | 10 | $207 |
Products named: KESIMPTA, ZEPOSIA, PONVORY, QULIPTA, TYSABRI, UBRELVY, Sunosi, VYVGART HYTRULO.
Industry payments across MD — which companies pay providers there.
